Our Take
A 26% relative risk reduction in stroke recurrence is solid, but the clinical bar for anticoagulants is how many bleeds you trade for every stroke prevented—and the trial shows asundexian achieved non-inferiority on major bleeding, not superiority.
Why it matters
Stroke prevention options remain limited; a new oral therapy with a novel mechanism (Factor XIa inhibition) could expand treatment choices for post-stroke patients who cannot tolerate or fail current antiplatelet agents. EMA validation opens the European market while FDA and China fast-track the global footprint.
Do this week
Neurology and thrombosis teams: request the full OCEANIC-STROKE trial results from *The New England Journal of Medicine* before June 2025 to compare asundexian's bleeding profile directly against your current second-line stroke recurrence protocols.
EMA begins review of Bayer's stroke-prevention drug
The European Medicines Agency has validated Bayer's marketing authorisation application for asundexian, an oral Factor XIa inhibitor designed to prevent ischaemic stroke in adults following a non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack (TIA). Validation signals the application is complete and triggers the EMA's centralised review procedure.
The application rests on data from OCEANIC-STROKE, a Phase III, double-blind, placebo-controlled trial that enrolled 12,327 participants worldwide. Researchers randomised patients to receive asundexian 50mg once daily plus antiplatelet therapy or placebo plus antiplatelet therapy. The primary efficacy endpoint measured time to ischaemic stroke; the primary safety endpoint was major bleeding per International Society on Thrombosis and Hemostasis (ISTH) criteria.
Results published in *The New England Journal of Medicine* found asundexian reduced ischaemic stroke by 26% (relative risk) without increasing major bleeding rates. The trial showed non-inferiority on bleeding safety, meaning asundexian did not raise the frequency of serious hemorrhagic events compared to placebo.
Bayer is pursuing regulatory approval across multiple regions. The US FDA granted asundexian priority review status, and China's Center of Drug Evaluation also assigned priority review. No country has yet approved asundexian.
Stroke burden is rising and treatment options remain constrained
Ischaemic stroke prevalence and mortality have both increased across EU member states. Between 2010 and 2019, prevalence rose 4% and stroke-related mortality climbed 7% (per Bayer's statement citing EU epidemiological data). Current standard care for post-stroke patients relies primarily on antiplatelet agents (aspirin, clopidogrel). Patients who cannot tolerate, fail, or are ineligible for these agents face limited alternatives.
Factor XIa is a coagulation pathway target distinct from conventional anticoagulants (warfarin, direct-acting anticoagulants) and antiplatelets. A mechanism that reduces clot formation without mimicking existing drug classes could offer clinicians a genuinely different option. The trial's non-inferiority on major bleeding—a historically contentious trade-off in stroke prevention—suggests asundexian does not incur the hemorrhage penalty that has limited some anticoagulant programs in post-stroke populations.
However, the magnitude of benefit (26% relative reduction) is meaningful but not exceptional in the stroke prevention field. Real-world adoption will depend on cost, convenience, tolerability, and how the drug performs in subgroups (age, comorbidity, prior antiplatelet failure)—details still to emerge from full manuscript publication and post-approval surveillance.
What neurologists and clinical pharmacists should do now
Obtain the full OCEANIC-STROKE manuscript from *NEJM* to evaluate bleeding rates by type (intracranial vs. gastrointestinal), any safety signals in specific subgroups, and relative efficacy against comparators beyond placebo. Compare the actual number needed to treat (NNT) and number needed to harm (NNH) against your institution's current second-line stroke recurrence protocols. Engage your thrombosis committee to draft potential integration pathways for post-stroke patients who fail or cannot tolerate antiplatelet monotherapy. Regulatory approval in Europe is expected within 12–18 months; US approval may follow sooner if the FDA's priority review timeline holds. Plan your institution's clinical evidence review and patient population screening now, not after market launch.